Patents by Inventor Mark Eben Massari

Mark Eben Massari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR THERAPEUTIC USE
    Publication number: 20210198218
    Abstract: Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.
    Type: Application
    Filed: August 10, 2020
    Publication date: July 1, 2021
    Inventors: Laurent Gomez, Mark Eben Massari
  • Compounds for therapeutic use
    Patent number: 10738018
    Abstract: Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: August 11, 2020
    Assignee: Dart Neuroscience, LLC
    Inventors: Laurent Gomez, Mark Eben Massari
  • COMPOUNDS FOR THERAPEUTIC USE
    Publication number: 20180251435
    Abstract: Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.
    Type: Application
    Filed: May 7, 2018
    Publication date: September 6, 2018
    Inventors: Laurent Gomez, Mark Eben Massari
  • Compounds for therapeutic use
    Patent number: 9963435
    Abstract: Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: May 8, 2018
    Assignee: Dart NeuroScience, LLC
    Inventors: Laurent Gomez, Mark Eben Massari
  • COMPOUNDS FOR THERAPEUTIC USE
    Publication number: 20180057470
    Abstract: Chemical entities of Formula (I): Including enantiomers thereof, wherein R1 has any of the values described herein, and compositions comprising such chemical entities; their preparation; and their use in various methods, including the treatment of depression, pain, cognitive disorders, neurodegenerative disorders, and other neurological and peripheral disorders.
    Type: Application
    Filed: August 31, 2016
    Publication date: March 1, 2018
    Inventors: Laurent Gomez, Mark Eben Massari
  • AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE
    Publication number: 20090209536
    Abstract: The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 20, 2009
    Applicant: KALYPSYS, INC.
    Inventors: Timothy Gahman, David Thomas, Hengyuan Lang, Mark Eben Massari
  • HETEROCYCLODIAZEPINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE
    Publication number: 20090062253
    Abstract: The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.
    Type: Application
    Filed: August 28, 2008
    Publication date: March 5, 2009
    Applicant: KALYPSYS, INC.
    Inventors: Timothy C. Gahman, Cunxiang Zhao, Hengyuan Lang, Mark Eben Massari
  • Trace amine receptor 1 of the african green monkey
    Publication number: 20080206786
    Abstract: A trace amine receptor 1 has been isolated from the genome of Cercopithecus aethiops (African green monkey). Described is the amino acid sequence of the receptor, the nucleic acid encoding the receptor, and methods for using the receptor to identify analytes that are agonists or antagonists of the receptor.
    Type: Application
    Filed: March 25, 2008
    Publication date: August 28, 2008
    Inventors: Mark Eben Massari, Herve Schaffhauser, Satoshi Ozaki
  • Trace amine receptor 1 of the African green monkey
    Patent number: 7368541
    Abstract: A trace amine receptor 1 has been isolated from the genome of Cercopithecus aethiops (African green monkey). Described is the amino acid sequence of the receptor, the nucleic acid encoding the receptor, and methods for using the receptor to identify analytes that are agonists or antagonists of the receptor.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: May 6, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Mark Eben Massari, Herve Schaffhauser, Satoshi Ozaki